Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of the MEK Inhibitor Mirdametinib in Histiocytic Disorders

NCT06153173 is registered in ClinicalTrials.gov with Children's Hospital Medical Center, Cincinnati as lead sponsor.

NCT NCT06153173
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06153173 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of the MEK Inhibitor Mirdametinib in Histiocytic Disorders
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Phase
Phase 2
Overall status
Recruiting
Start date
February 5, 2024
Completion date
March 31, 2031
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

histiocytic disorders, juvenile xanthogranuloma (jxg), langerhans cell histiocytosis (lch), rosai-dorfman disease (rdd)